investors

Press Releases

DateTitle and SummaryView
February 13, 2018
Strengthened Financial Condition Supports Continued Advancement of Stem-to-T-Cell Program
ImmunoCellular Therapeutics Announces Update on Financial Condition
December 13, 2017
Completes Important First Step toward Production of Unlimited Killer T Cells Designed to Attack Cancer Cells
ImmunoCellular Therapeutics Achieves Key Milestone in Stem-to-T-Cell Research Immuno-Oncology Program
November 22, 2017
Live presentation will take place on December 7, 2017 at 9:30 a.m. PT (12:30 p.m. ET)
ImmuncoCellular Therapeutics to Present at the 10th Annual LD Micro Main Event on December 7, 2017
November 21, 2017
-Continued Focus on Stem-to-T-Cell Program-
-Strengthened Financial Condition-
-Conference Call Today at 5:00 pm ET-
ImmunoCellular Therapeutics Announces Third Quarter 2017 Financial Results
November 17, 2017
LOS ANGELES , Nov. 17, 2017 /PRNewswire/ --  ImmunoCellular Therapeutics, Ltd. (" ImmunoCellular ") (NYSE MKT: IMUC) today announced that it plans to report third quarter 2017 financial results on Tuesday, November 21, 2017 . The Company also plans to hold a conference call and webcast on that day
ImmunoCellular Therapeutics to Report Third Quarter 2017 Financial Results on November 21, 2017
October 3, 2017
Live presentation will take place on October 11, 2017 at 2:00pm ET / 11:00am PT; Replay available on demand
ImmunoCellular Therapeutics to Present at the Lytham Partners Virtual Investor Conference on October 11, 2017 at 2:00pm ET
September 13, 2017
LOS ANGELES , Sept. 13, 2017 /PRNewswire/ --  ImmunoCellular Therapeutics, Ltd.  (" ImmunoCellular " or the "Company") (NYSE MKT: IMUC) today announced that the NYSE MKT LLC (the "NYSE MKT") has accepted the Company's plan to regain compliance with the exchange's continued listing standards set
ImmunoCellular Therapeutics Announces NYSE MKT Acceptance of its Plan of Compliance
August 23, 2017
- Near-Term Milestones Anticipated in Stem-to-T-Cell Research Program -
- Restructuring Underway Designed to Achieve Cost Savings and Extend Operating Runway -
- Conference Call and Webcast Today at 5:00 pm ET -
ImmunoCellular Therapeutics Provides Business Update on Research and Development Programs and Future Strategy
August 14, 2017
-Company to Host Business Update Conference Call and Webcast on August 23, 2017-
ImmunoCellular Therapeutics Announces Second Quarter 2017 Financial Results
July 18, 2017
LOS ANGELES , July 18, 2017 /PRNewswire/ --  ImmunoCellular Therapeutics, Ltd.  (" ImmunoCellular ") (NYSE MKT: IMUC) today announced the pricing of an underwritten public offering of 5,000 shares of its Series B 8% Mandatorily Convertible Preferred Stock ("Preferred Stock") and related warrants
ImmunoCellular Therapeutics Announces Pricing of Public Offering of Convertible Preferred Stock and Warrants
Copyright 2018 by Immunocellular Therapeutics, Ltd.
All Rights Reserved